NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

Fresenius Kabi building
Fresenius Kabi will expand its drug-manufacturing operations in Wilson, potentially bringing at least 445 new jobs over five years and $100 million in investment.

The U.S. Food and Drug Administration has approved ViiV Healthcare’s two-drug, once-a-day tablet combination to treat infection by a certain type of the human immunodeficiency virus (HIV).

The therapy, Juluca, consists of two previously approved drugs, dolutegravir and rilpivirine. It is the first approved HIV treatment that combines two drugs instead of three or more used in standard HIV treatment. And it's significant that it's a once-daily tablet.

Camras Vision Logo
Camras Vision, developer of a new medical device for treating glaucoma, won the Emerging Company Award at SEBIO’s 19th Annual Investor and Partnering Forum in Pinehurst. The honor came a few days before the company expects to close on $5 million in Series A financing.

Ken Tindall, Ph.D.

Ken Tindall, Ph.D., senior vice president of science and business development at the North Carolina Biotechnology Center, has won Southeast BIO’s Leadership Award, one of several honors announced at SEBIO’s 19th Annual Investor and Partnering Forum in Pinehurst.

Half of U.S. honeybee colonies have been wiped out in the last decade, which worries many in agriculture since a third of our food relies on honeybee fertilization.
IQVIA logo

Thirty-five years after its founding in 1982, Durham-based QuintilesIMS has retired its name for a new one, IQVIA (pronounced as “I-Q-via”).

Shares of IQVIA will trade on the New York Stock Exchange under the new ticker symbol IQV, effective Nov. 15.

Locus Biosciences logo
Locus Biosciences, born with the help of two loans from the North Carolina Biotechnology Center, has raised $19 million in Series A funding from major investors.

Are you ready for chicken tenders that taste and chew like the real thing, even though they’re made from plant protein without a bit of chicken? A Triangle-based company, Improved Nature, already has them and other plant-based meat-like products on the market.

That was only one of the advanced food technologies discussed by a panel of innovators at the North Carolina Professional Ag Biotech forum Wednesday at the North Carolina Biotechnology Center.

Others included:

Arbiom LogoWood, the traditional source of pulp, paper, packaging, biofuels and other industrial products, may soon find its way into fish feed bins and onto dinner plates with the use of new processing technologies developed by a North Carolina biotechnology company.

RedHill Biopharma logo
RedHill Biopharma, an Israeli company with U.S. headquarters in Raleigh, has received orphan drug designation for its pancreatic drug candidate from the U.S. Food and Drug Administration.
Syngenta logo
Swiss-based Syngenta, which has its U.S. headquarters in Greensboro and its Advanced Crop Lab in Research Triangle Park, has obtained a non-exclusive license from the Broad Institute of MIT and Harvard to use CRISPR-Cas9 genome editing technology for agriculture applications.
Baebies SEEKER diagnostic system - Baebies photo
Baebies SEEKER diagnostic system -- Baebies photo

Durham-based Baebies Inc., a developer of products and services for newborn screening and pediatric testing, has closed on $10 million in Series B financing.

The North Carolina Biotechnology Center awarded 28 grants, loans and fellowships totaling $1.8 million in the first quarter of its 2017-2018 fiscal year ending Sept. 30.
North Carolina companies presenting at the 19th annual Southeast BIO Investor & Partnering Forum offer participants access to technologies to treat heart arrhythmias, lung disease, glaucoma, bacterial infections, and addiction.